Dr. Kevin Rosenblatt is the chief scientific officer at Healix Pathology. He has more than 30 years of clinical and biomedical research and development experience in multiple settings, including academia, biotech, startups, and clinical practice. Dr. Rosenblatt has published more than 80 peer-reviewed articles and book chapters on cancer, neuronal biology, biomarker development, and clinical genomics and proteomics and gives lectures at various national and international meetings. After graduating from the combined MD-PhD program at the University of Texas Southwestern, he completed his residency and a research fellowship in cancer signaling and predictive biomarkers at the National Cancer Institute. Dr. Rosenblatt served as Director of the Center for Clinical Proteomics at the Brown Foundation Institute of Molecular Medicine and as the Director of the Clinical and Translational Proteomics Service Center at the UT Health Science Center. He was Associate Professor in the Division of Oncology, Department of Internal Medicine at UT Health and the McGovern Medical School and Associate, Adjunct Professor in the School of Health Professions at the MD Anderson Cancer Center.
Undergraduate: 1988, Tulane University
Chemistry and Judaic Studies
University of Texas Southwestern Medical School
University of Texas Southwestern Graduate School for the Biomedical Sciences, Neurosciences